eligibility_summary
Eligible: <5 yrs with newly diagnosed CNS embryonal tumors (medulloblastoma non‑SHH, ETMR, pineoblastoma, ATRT, embryonal NOS), Lansky ≥60, adequate counts/organ function, SpO2 >90%, consent, sufficient frozen tumor tissue, able to undergo pheresis and Rickham reservoir placement, stable neuro exam on stable/decreasing steroids. Exclude: uncontrolled infection/HIV, investigational immunotherapy or T‑cell mAbs <28d, bulky tumors, dexamethasone >0.05 mg/kg.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Intervention: Autologous adoptive cellular therapy using multi–tumor antigen–specific cytotoxic T lymphocytes (TSA‑T), an ex vivo–expanded T‑cell product. Mechanism: TCR-mediated recognition of personalized tumor-specific antigens (neoantigens) identified via proteogenomic profiling from each patient’s tumor, CTLs kill targets via perforin/granzyme after MHC-restricted peptide recognition. Delivery is intraventricular to maximize CNS exposure post-chemotherapy/stem-cell rescue. Targets: Tumor cells from embryonal pediatric brain tumors (medulloblastoma [non‑SHH], ETMR, pineoblastoma, ATRT, embryonal NOS) expressing individualized TSAs. Pathways: Antigen processing and presentation (MHC class I/II), CD8+ (and supportive CD4+) T-cell activation and cytotoxic effector pathways within the CNS microenvironment.